Quinn Opportunity Partners LLC Has $1.38 Million Position in Janux Therapeutics, Inc. $JANX

Quinn Opportunity Partners LLC lifted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 15.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 59,893 shares of the company’s stock after purchasing an additional 8,000 shares during the period. Quinn Opportunity Partners LLC owned 0.10% of Janux Therapeutics worth $1,384,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of JANX. US Bancorp DE grew its holdings in Janux Therapeutics by 2,402.9% during the first quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after purchasing an additional 1,658 shares during the period. FNY Investment Advisers LLC increased its holdings in shares of Janux Therapeutics by 111.8% during the 2nd quarter. FNY Investment Advisers LLC now owns 5,210 shares of the company’s stock worth $120,000 after acquiring an additional 2,750 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Janux Therapeutics by 26.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,125 shares of the company’s stock valued at $192,000 after acquiring an additional 1,488 shares during the period. AlphaQuest LLC lifted its holdings in Janux Therapeutics by 3,658.9% during the 2nd quarter. AlphaQuest LLC now owns 9,698 shares of the company’s stock valued at $224,000 after purchasing an additional 9,440 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in Janux Therapeutics by 8.1% during the 2nd quarter. ProShare Advisors LLC now owns 10,284 shares of the company’s stock valued at $238,000 after purchasing an additional 771 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Stock Down 1.2%

JANX opened at $28.52 on Thursday. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -16.98 and a beta of 2.83. Janux Therapeutics, Inc. has a twelve month low of $21.73 and a twelve month high of $71.71. The company has a 50-day simple moving average of $25.43 and a 200 day simple moving average of $25.17.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.21. The firm had revenue of $10.00 million during the quarter, compared to analyst estimates of $3.07 million. Sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

JANX has been the topic of several research analyst reports. Stifel Nicolaus reissued a “buy” rating and issued a $45.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Guggenheim initiated coverage on shares of Janux Therapeutics in a research note on Wednesday, September 3rd. They issued a “buy” rating and a $72.00 price target on the stock. Barclays raised their price objective on shares of Janux Therapeutics from $47.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Wedbush reaffirmed an “outperform” rating and issued a $76.00 target price on shares of Janux Therapeutics in a research report on Friday, November 7th. Finally, Piper Sandler initiated coverage on Janux Therapeutics in a research note on Monday, August 18th. They set an “overweight” rating and a $42.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.17.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 16,665 shares of Janux Therapeutics stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $30.06, for a total value of $500,949.90. Following the transaction, the insider owned 82,139 shares in the company, valued at approximately $2,469,098.34. This trade represents a 16.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 8.10% of the company’s stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.